Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Priming anticancer active specific immunotherapy with dendritic cells.

Simone Mocellin1

  • 1Department of Oncological & Surgical Sciences, University of Padova, via Giustiniani 2, 35128 Padova, Italy. simone.mocellins@unipd.it

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Promotion for Sun Protection: A Community Approach in a Mountain Setting.

High altitude medicine & biology·2026
Same author

Laser-based therapies in the management of non-melanoma skin cancers: a narrative review.

Lasers in medical science·2026
Same author

The Role of Laser Modalities in Melanoma Management: Critical Analysis of Local Control and Palliative Applications.

Cancers·2026
Same author

Clinicopathologic Features and Treatment Outcomes of Squamoid Eccrine Ductal Carcinoma: A Comprehensive Retrospective Series.

The American Journal of dermatopathology·2026
Same author

Impact on Quality of Life and Psychological Dimensions in Caregivers of Melanoma and Sarcoma Patients: A Scoping Review.

Cancers·2026
Same author

A novel polymorphism in the TERT gene is associated with lower survival in male patients with melanoma.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Dendritic cell (DC) vaccines show promise for cancer treatment, but clinical results vary. Understanding DC biology and immune interactions is key to improving cancer immunotherapy effectiveness.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are potent immunological adjuvants for cancer vaccines.
  • Clinical outcomes of DC-based vaccines have not fully met initial expectations.
  • The complexity of the immune system presents challenges for DC-based immunotherapy.

Purpose of the Study:

  • To explore the potential of dendritic cells (DCs) in active specific immunotherapy against cancer.
  • To understand the factors influencing the efficacy of DC-based cancer vaccines.
  • To identify conditions for effective immune-mediated cancer eradication.

Main Methods:

  • Review of clinical findings on DC-based immunotherapy in humans.
  • Analysis of immune system polarization against malignant cells.

Related Experiment Videos

  • Investigation of tumor-host immune system interactions.

    • Main Results:

    • DC-based immunotherapy can actively polarize the immune system against cancer cells.
    • Tumor regression has been observed in some patients receiving DC-based treatments.
    • The immune system can be harnessed as an endogenous weapon against cancer.

    Conclusions:

    • Effective cancer immunotherapy requires a deep understanding of DC biology.
    • Optimizing DC-based vaccines necessitates comprehending tumor-host immune interactions.
    • Reproducing successful outcomes in more patients depends on elucidating cellular and molecular conditions for effective cancer eradication.